Previous close | 8.60 |
Open | 15.78 |
Bid | 15.85 |
Ask | 16.25 |
Strike | 60.00 |
Expiry date | 2024-07-19 |
Day's range | 15.78 - 15.78 |
Contract range | N/A |
Volume | |
Open interest | 330 |
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.